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Abstract  
Identifying genetic variants with pleiotropic associations can uncover common pathways influencing 
multiple cancers. We took a two-staged approach to conduct genome-wide association studies for lung, 
ovary, breast, prostate and colorectal cancer from the GAME-ON/GECCO Network (61,851 cases, 61,820 
controls) to identify pleiotropic loci. Findings were replicated in independent association studies (55,789 
cases, 330,490 controls). We identified a novel pleiotropic association at 1q22 involving breast and lung 
squamous cell carcinoma, with eQTL analysis showing an association with ADAM15/THBS3 gene 
expression in lung. We also identified a known breast cancer locus CASP8/ALS2CR12 associated with 
prostate cancer, a known cancer locus at CDKN2B-AS1 with different variants associated with lung 
adenocarcinoma and prostate cancer and confirmed the associations of a breast BRCA2 locus with lung 
and serous ovarian cancer. This is the largest study to date examining pleiotropy across multiple cancer-
associated loci, identifying common mechanisms of cancer development and progression.  
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Introduction 
Genome wide association studies (GWAS) have identified hundreds of genetic variants that are 
associated with risk of specific cancers (1). It has been observed that some chromosomal regions show 
pleiotropic associations, where the same genetic loci are associated with different cancers. One of the 
first identified pleiotropic loci is at 8q24, where genetic variants are associated with breast, prostate, 
colorectal and ovarian cancer risk, with some of the variants only associated with one cancer, while 
others are associated with multiple cancers (2). Similarly, genetic variants at the TERT-CLPTM1L region 
at 5p15.33 are associated with risk of lung, bladder, prostate, and other cancers (3).  
The identification of pleiotropic loci is an important step in elucidating cancer etiology by understanding 
common pathways that influence carcinogenesis across different tumors, and in improving knowledge 
of cancer susceptibility. Furthermore, analyzing genomic data across multiple cancer sites might identify 
novel susceptibility loci, as variants that do not meet the stringent criteria for GWAS significance for any 
one cancer site, might show significant associations when multiple cancers are analyzed together (4).  
Our investigation used data from the Genetic Associations and Mechanisms in Oncology (GAME-ON) 
Network and the Genetic and Epidemiology of Colorectal Cancer Consortium (GECCO) (5). The GAME-ON 
Network was launched by the National Cancer Institute (NCI) to capitalize on the extensive investment 
in GWAS, with the overarching goal to integrate post-GWAS research and to facilitate analyses that 
address research questions that are common across multiple cancer sites. The GAME-ON Network is 
focused on tumors that currently represent a major public health burden and has assembled extensive 
genomic data from consortia investigating the cancer sites which constituted the basis of our cross-
cancer analysis. We use these data and independent replication studies to investigate pleiotropic 
associations across lung, breast, colorectal, ovary and prostate cancer using GWAS results for 61,851 
cases and 61,820 controls, the largest investigation of pleiotropic associations to date. 
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Materials and Methods 
Data and contributing consortia 
This study used summary level data to perform cross-cancer GWAS analysis of lung, colorectal, prostate, 
breast and ovarian cancers using a subset-based meta-analytical approach. Forty-six studies from North 
America and Europe organized into cancer site specific consortia within the GAME-ON Network 
(http://epi.grants.cancer.gov/gameon/) or GECCO, participated. Table 1 provides details for contributing 
consortia and studies. Analyses also included the following subtypes: adenocarcinoma and squamous 
cell carcinoma of the lung; the aggressive form of prostate cancer; estrogen receptor negative breast 
cancer, and serous and endometrioid cancers of the ovary (Table 1). All studies frequency matched 
cases and controls on at least age and gender. All subjects were of European descent. 
Genotyping and imputation 
Genotyping was performed on Affymetrix or Illumina platforms (Table 1). Standard marker exclusion 
criteria were applied in each cancer consortium (5-11), and we have previously reported the summary of 
QC details in Hung et al. (12). Genotype imputation was conducted for each cancer site using IMPUTE, 
BEAGLE, MACH and Minimac (imputation threshold of R2 > 0.3) using the 1000 genome reference panel. 
Statistical Analysis 
Logistic regression analysis using a log additive model was performed previously to test variant 
associations with cancer risk for the forty-five studies (5-11), providing per-allele odds ratios (ORs) 
adjusted for age, principal components and gender where applicable. Study-specific results were then 
combined for each cancer site using a fixed effects model.  
A subset-based meta-analysis approach developed by Bhattacharjee et al. (ASSET) was used to 
investigate pleiotropic effects across cancer sites (4). The method generalizes the standard fixed effect 
meta-analysis by examining the association between a genetic variant and multiple subsets of cancers, 
allowing opposing direction of effects and null associations. Associations are summarized with an overall 
two-sided P value. A multiple-testing adjustment procedure (based on statistical theory for tail-
probability approximation) maintains appropriate type I error rates. Analysis was performed when at 
least three cancer sites had data. 
Accounting for subsets of studies with no effects and/or effects in opposing directions (i.e., both 
increased and reduced risk subsets) is an advantage of the subset-based meta-analysis approach. 
However, when a large majority of underlying associations are in one direction, subset meta-analysis 
can have lower power than standard fixed effects analysis.  We therefore explored results using 
standard fixed effects meta-analysis (when data was present for all cancer sites), again using ASSET.  
Subjects appearing in several studies with different cancer sub-types (e.g., overlapping controls for lung 
adenocarcinoma and lung SqCC) and across cancer types (e.g., overlapping controls from the Welcome 
Trust Case Control Consortium (WTCCC) for UK ovary and UK breast GWAS) were accounted for in the 
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covariance matrix when estimating standard errors for subset-based and standard meta-analyses.   
In order to find robust pleiotropic associations we first identified variants that showed evidence for 
pleiotropy and then sought to validate the individual variant cancer site associations in replication data 
sets. To prioritize variants for replication, we selected those with P < 5 x 10-7 based on the two sided 
subset-analysis test, the positive and negative associations that contributed to the two-sided subset-
analysis test signal, and the fixed effect meta-analysis. We excluded variants where associations were 
obviously driven by a single cancer site. We also selected variants associated with at least two cancers 
(including subtypes) at P < 5 x 10-3. Among variants selected, we further prioritized for validation those 
showing the strongest pleiotropic association in a region (based on subset or standard cross cancer 
meta-analysis), as well as those representing association peaks in site-specific analyses. We then sought 
to validate these specific variant-cancer site associations using independent study populations of 
European descent with all five cancers from deCODE (10,13 ), lung cancer from Harvard (14,15), breast 
(region 1q22 only) from iCOGS, ovarian from OCAC/iCOGS and prostate from PRACTICAL/iCOGS (7,8,16). 
For cross-ethnicity generalizability, we examined results for the selected variants in different 
race/ethnicities using data from Japan (lung (17)), Nanjing (lung (18)), Shanghai (breast (19)), MEC, 
African American Breast Cancer GWAS Consortium (AABC), African Ancestry Prostate Cancer GWAS 
Consortium (AAPC), and San Francisco (breast for Latinas) (20-23). An outline of analysis steps is 
presented in supplemental figure 1. 
Further investigation of pleiotropic effects 
We further investigated pleiotropy between cancer sites using conditional Q-Q plots to examine 
enrichment of association signals in one cancer when conditioning on significance of P values of a 
second cancer. Enrichment is reflected in a leftward deflection of the Q-Q plot with decreasing P value 
categories of the conditioning cancer (24), indicating higher pleiotropy between cancer sites than 
expected by chance. 
Functional Significance  
eQTL analysis 
We obtained non-tumor lung eQTL data of 1,111 patients from three studies: Laval University (n = 409, 
GSE23352), The University of British Columbia (n = 339) and the University of Groningen (n = 363). Gene 
expression profiles were obtained using an Affymetrix array (GEO platform GPL10379). Genotyping was 
performed using the Illumina Human1M-Duo genotyping BeadChip. Analyses were adjusted for age, sex 
and smoking status. eQTL data are deposited in the Gene Expression Omnibus (GEO) database with 
accession numbers GSE23352, GSE23529 and GSE23545 for the three studies respectively. Further 
details of this study are published elsewhere (25). We investigated validated lung cancer associated 
variants from our study. A statistically significant eQTL for a variant was declared if 2 of 3 studies 
showed a significant P value after Bonferroni correction for multiple comparisons. We also evaluated 
eQTL data for variants in LD (R2 > 0.7) with our validated variants. We also obtained TCGA eQTL data for 
402 high-grade serous ovarian cases and 145 prostate tumor samples again investigating variants with 
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validated associations and those in high LD (R2 > 0.7) with them. Gene expression values for high-grade 
serous ovarian cases were assessed by P value.  Gene expression values for prostate cancer were 
adjusted for somatic copy number and CpG methylation as previously described (26). Significant 
associations were defined as those having both P value and false discovery rate (Benjamini-Hochberg 
method) of less than 0.05. 
Function/prediction 
 
We used FuncPred from SNPinfo (http://snpinfo.niehs.nih.gov/) to assist with variant function 
prediction. The software evaluates a variant’s potential function in splicing regulation, TFBS prediction, 
miRNA binding site prediction and regulatory potential using in-house algorithms and tools developed 
elsewhere. In addition, we used RegulomeDB to further assess regulatory potential for variants of 
interest (http://www.regulomedb.org/). This tool includes high-throughput, experimental data sets from 
ENCODE and other sources, as well as computational predictions and manual annotations to identify 
putative regulatory potential and functional variants. We further examined ENCODE data using the UCSC 
genome browser (https://genome.ucsc.edu/) (see Supplementary Materials: Bioinformatics Tools). 
 
Results 
After applying quality control filters 9,916,564 variants were analyzed for pleiotropic associations using 
61,851 cases and 61,820 controls of European ancestry across five common cancer sites in the GAME-
ON Network and GECCO (GAME-ON/GECCO) (Table 1). Figure S2 displays an overview of the association 
test results for each of the five main cancer sites investigated.  
One hundred and ninety variants in 33 regions (13 to 22 for each cancer site) were prioritized for follow-
up for replication in Caucasian populations (55,789 cases and 330,490 controls) and generalizability 
(18,152 cancer cases and 21,410 controls) after the initial analysis (see Table 1 and Supplementary Table 
S1). An additional 46,785 cases and 42,892 controls from iCOGS Breast cancer were used for validation 
of the novel pleiotropic locus at 1q22 (see below). We replicated associations at four of the 33 regions 
selected for follow-up in Europeans. Variants with replicated pleiotropic associations were not 
associated with cancer risk in other ethnic populations and therefore these data are not presented. The 
main findings in each region are described below (see supplementary Table S1 and S2 for summary).  
 
Novel region: 1q22 for lung squamous cell carcinoma and breast cancer  
Standard meta-analysis of GAME-ON/GECCO discovery data identified an association between 
rs1057941 located at 1q22 and overall risk of cancer (P = 1.74 x 10-7, Fig. 1). Overall lung, lung squamous 
cell carcinoma (lung SqCC) and breast cancer were strongly associated with this variant in GAME-
ON/GECCO data (Lung: OR = 1.08, 95% CI 1.05-1.12, P = 9.2 x 10-6; lung SqCC: OR = 1.10, 95% CI 1.04-
1.16, P = 0.001; Breast: OR = 1.07, 95% CI 1.04-1.11, P = 6.08 x 10-5). The association for lung SqCC was 
replicated in deCODE and Harvard studies combined, with OR of 1.12 (95% CI 1.01-1.23, P = 0.03). The 
association with breast cancer was replicated in deCODE and iCOGS combined (OR = 1.03, 95%CI 1.01-
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1.05, P = 0.004). The overall P value for association from both stages for lung SqCC and breast cancer 
approached genome-wide significance (P = 7.9 x 10-8) (Fig. 1).  
The aggressive form of prostate cancer was also selected by ASSET as part of the subset of cancers 
associated with rs1057941. We have no replication data for this subtype and did not replicate the 
association with overall prostate cancer (deCODE and PRACTICAL/iCOGS combined: OR = 1.02, 95% CI 
1.00-1.05, P = 0.08).  
Regional plots constructed from GAME-ON/GECCO results show a distinct peak in P values represented 
by rs1057941 in a 40kb region of LD at 1q22 that includes KRTCAP2, GBA, MTX1, MUC1, TRIM46, THBS3, 
ADAM15 and ASH1L for the cross-cancer analysis (Fig. 2A), while for individual sites MUC1 variant 
rs4072037 was most significant for lung SqCC (P = 3.21 x 10-4) and the TRIM46 variant, rs3814316, for 
breast cancer (P = 3.06 x 10-6). These 3 variants are in high to complete LD with each other with pair-
wise D’ of 0.86 (rs1057941-rs3814316) or 1.00 (rs1057941-rs4072037, and rs3814316-rs4072037). 
eQTL analyses indicated that rs4072037 acted as a normal lung tissue eQTL for two genes in this region, 
ADAM15 and THBS3, with two studies showing significant associations after adjustment for multiple 
comparisons and the third showing a nominally significant association consistent in direction with the 
other two (ADAM15: Laval P = 2.39 x 10-7,  University of British Columbia P = 4.09 x 10-5, University of 
Groningen P = 0.08; THBS3: Laval P = 1.71 x 10-5,  University of British Columbia P = 4.15 x 10-6, University 
of Groningen P = 0.004) (Fig 2B). ADAM15 is of primary interest as it was shown to be overexpressed in 
lung and breast cancer (27). The risk allele for rs4072037, A, was consistently associated with increased 
ADAM15 gene expression in all three studies. In the UBC discovery set rs4072037 was the strongest 
eQTL among 33 variants. 
 
Previously known cancer loci with pleiotropic associations 
 
2q33.1 (known breast and melanoma locus) and prostate cancer 
We identified a pleiotropic association between rs13016963 located in 2q33.1 and prostate (OR = 1.08, 
95% CI 1.04-1.13, P = 3.05 x 10-5) and breast cancer (OR = 0.93, 95% CI 0.90-0.96, P = 5.75 x 10-5) (Fig. 3A) 
in GAME-ON/GECCO. This variant is in intron 5 of ALS2CR12, adjacent to CASP8 (Fig. 3B), and was 
associated with melanoma in a previous GWAS (28). The region was previously identified as harboring 
variants associated with breast cancer risk (29-31) and the association found with breast cancer can be 
explained through LD (R2 = 0.74) with one of these (rs1830298, P value for breast cancer association = 
1.02 x 10-7). The association with prostate cancer has not been previously reported and we replicated it 
in deCODE and iCOGS (OR = 1.05, 95% CI 1.03-1.08, P = 7.6 x 10-5) (Fig. 3A). The combined GAME-
ON/GECCO, deCODE and iCOGS P value was 1.9 x 10-8.  
In Figure 3C, we show eQTL analysis results for rs1035142, which was in perfect LD with rs13016963 in 
the eQTL data set and was associated with BZW1 (P = 0.001, FDR = 0.04). This variant had the strongest 
association signal among those investigated. We do note that there were variants with more significant 
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associations with BZW1 expression that fell outside of the LD range of R2≥ 0.70 with rs13016963 (e.g., 
rs13113, P = 4.9 x 10-6, R2 = 0.62). This suggests there are other potential cis-eQTL candidates for BZW1 
in the region.  
9p21.3 (known lung SqCC and breast locus) and lung adenocarcinoma 
Similar to 8q24, the 9p21.3 region displays a complex nature of associations with multiple cancer sites. It 
was previously known to be associated with lung SqCC and breast cancer. In our analysis based on 
GAME-ON/GECCO discovery data, we observed suggestive evidence of association between the variant 
rs62560775 at CDKN2B-AS1 and lung adenocarcinoma (OR = 1.19, 95% CI =1.08-1.31, P = 2.77 x 10-4), as 
well as breast cancer (OR = 1.11, 95% CI 1.05-1.17, P = 5.30 x 10-4). Although this region was previously 
reported as a lung SqCC susceptibility locus, this is the first time that we observed an association with 
lung adenocarcinoma. The association was replicated based on deCODE and Harvard data (OR = 1.16, 
95% CI 1.03-1.30, P = 0.01). The combined (both stages) P value was 1.0 x 10-5 (Fig. 4A). The association 
of this variant with lung adenocarcinoma was the most significant in the region (Fig. 4B).  Our lung eQTL 
investigation of this variant showed no significant association with gene expression in this region.  
Another variant in the same region, rs1011970, was shown to be associated with prostate cancer (OR = 
1.10, 95% CI = 1.05-1.15, P = 7.3 x 10-5). This variant was found to be associated with breast cancer in a 
previous GWAS (32). The association with prostate cancer was replicated in deCODE and iCOGS 
combined (P = 0.001). The combined P value based on both stages was 9.5 x 10-7 (Fig 4C). The regional 
plots shows that this variant had the second most significant association with prostate cancer in the 
region. (The peak association for prostate cancer is represented by rs72652411, a variant not associated 
with any cancer other than prostate (Fig. 4D)).  
13q13.1 (known breast and lung locus) confirmed for serous ovarian cancer 
We observed a significant pleiotropic associations for rs11571833 (ASSET two-sided P value: = 6.14 x 10-
10). This variant (Fig. S3) is potentially functional and genome-wide significant associations between this 
variant and breast and lung cancer (driven by SqCC) were previously reported, with the latter study 
using a subset of the lung cancer data use here (7,10). More recently, a study focusing specifically on 
rs11571833 reported an association with serous ovarian cancer using the iCOGS data which formed our 
replication data set (P = 3 x 10-5).  Our results from the GAME-ON data set confirm the association with 
serous ovarian cancer (GAME-ON OR = 1.76, 95% CI 1.30-2.39; P = 2.49 x 10-4; with the rare allele 
associated with increased risk)) and reached genome-wide significance when we combined the two data 
sets (P = 3.95 x 10-8) (Fig S3). We did not replicate the association with breast cancer; however this might 
be due to a lack of power to detect an association for this rare variant in our sample. 
Other evidence for pleiotropic associations 
As demonstrated by the leftward deflection of Q-Q plots with decreasing P value category, there is 
evidence of pleiotropic associations for breast and ovarian cancer (supplementary Fig. S4A), breast and 
prostate cancer (supplementary Fig. S4B) and prostate and colorectal cancer (supplementary Fig. S4C).  
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There was no evidence of pleiotropic associations for prostate and ovary cancer (Fig. S4D), or lung 
cancer with any of the other four cancer sites.   
 
Discussion 
Using data from the GAME-ON Network and GECCO we conducted a cross-cancer GWAS analysis 
investigating pleiotropic associations for five cancer sites (lung, breast, colorectal, ovary and prostate) 
including histology and subtypes. We identified three new pleiotropic associations that were supported 
by results in GAME-ON/GECCO data and our independent replication data sets. We identified a novel 
pleiotropic association at the 1q22 region involving breast cancer and lung SqCC, neither of which was 
previously known to be associated with genetic variation in this region. The association with lung SqCC 
was further supported by its functional significance as demonstrated by eQTL analysis. Further novel 
results include a locus at CASP8/ALS2CR12, known to be associated with breast cancer and melanoma, 
that was found to be associated with prostate cancer; while genetic variation at the 9p21.3 region, 
known to be associated with breast cancer and lung SqCC, appears to be associated with lung 
adenocarcinoma and prostate cancer. We also confirmed an association between a known lung and 
breast cancer locus at BRCA2 with serous ovarian cancer risk. 
The locus at 1q22 represented by rs1057941, rs3814316 and rs4072037 lies in a region of LD that 
includes KRTCAP2, MTX1, TRIM46, MUC1, GBA, THBS3, ADAM15 and ASH1L. Of these variants, 
rs4072037 at MUC1 might be functional as it was shown to regulate alternative splicing of the second 
exon in MUC1 and modifies the gene’s transcriptional activity (33). Aberrantly glycosylated MUC1 is 
overexpressed in most epithelial cancers and is known to have an oncogenic effect. It mediates the 
production of growth factors such as connective tissue growth factor (CTGF), and platelet driven growth 
factor A and B (PDGF-A and PDGF-B) that promote activation of the MAPK and PI3k/Akt  pathways 
potentiating proliferation and survival of tumor cells (34). It also plays a critical role in EGFR signalling, 
promoting survival of NSCLC cells (35).  
Our lung eQTL investigation found no association with MUC1 expression but the risk allele, A, of 
rs4072037 was associated with increased expression of two other genes in the region (ADAM15 and 
THBS3). This result suggests other mechanisms by which this variant could influence cancer risk. 
ADAM15 is of particular interest since it was shown to be overexpressed in both lung and breast cancer 
(27), consistent with our finding of pleiotropic associations of these two cancer sites. Overexpression in 
breast cancer is associated with Her2/neu expression and evidence from breast cancer cell lines 
indicates that ADAM15 catalyzes the cleavage of E-cadherin which in turn binds to and enhances ErbB 
receptor signalling (36). A recent meta-analyses provided support for an association of this variant with 
gastric cancer in Asian populations (37), and a recent GWAS in the Icelandic population also suggested 
an association between this region and gastric cancer in European populations.  These results lend 
further support for the etiological role of this region on cancer susceptibility in general (38).    
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For 2q33.1, we found evidence for a pleiotropic effect for rs13016963 (at ALS2CR12) on breast and 
prostate cancer. This region is known to harbor breast cancer susceptibility loci: rs1045485, encoding 
the missense alteration D302H in CASP8 (adjacent to ALS2CR12)(29), rs1830298 (mentioned above) at 
ALS2CR12 and rs1045494 at CASP8 (30,31).  Of these three variants, rs1830298 was found to have the 
most significant association with breast cancer (P = 1.02 x 10-7) in our study, and was associated with 
prostate cancer risk (P = 5.2 x 10-4); whereas rs1045485 and rs1045494 were not. For prostate cancer, 
rs13016963 represented the peak association, although we point out strong LD between rs13016963 
and rs1830298 (R2 = 0.74). Interestingly, rs13016963 was also found to be associated with risk of 
melanoma in a previous GWAS in subjects of European descent (28) indicating this variant may be 
associated with both prostate cancer and melanoma in Caucasian populations. It was also found to be 
associated with esophageal squamous cell carcinoma in Han Chinese (39).  
Previous research has examined associations between other genetic variants in this region and prostate 
cancer risk. A possible association between the CASP8 histidine variant D302H and the more aggressive 
form of prostate cancer in European populations was reported (40). This variant was however not 
associated with aggressive prostate cancer (P = 0.11) or overall prostate cancer (P = 0.14) in GAME-
ON/GECCO.  
Our prostate eQTL analysis suggested that rs13016963 influences the expression of BZW1. Previous 
studies indicate a role for BZW1 in carcinogenesis. BZW1 can activate histone H4 gene transcription and 
serves as a co-regulator of other transcription factors involved in cell cycling. It has been implicated in 
promoting mucoepidermoid carcinoma tumor growth (41). We also found two potential functional 
variants in the region (rs700636 and rs1035142). These variants are in strong LD with rs13016963 
(R2≥0.93), and have associations with prostate cancer similar to rs13016963 in strength and are 
predicted to sit in miRNA binding sites.  
The 9q21.3 region encoding CDKN2B-AS1 has been much studied in cancer research. We observed a 
pleiotropic association of rs62560775 (located in the intronic region of CDKN2B-AS1) involving lung 
adenocarcinoma and breast cancer. The association with breast cancer might to be due to LD (R2 = 0.38) 
with a previously identified breast cancer susceptibility variant, rs1011970. Interestingly, we did 
replicate an association between rs1011970 and prostate cancer, suggesting this specific variant, or 
variants in LD with it contribute to risk for both breast and prostate cancer. Timofeeva et al, found an 
association between this region and lung SqCC, represented by rs1333040 (42), but this variant was not 
associated with adenocarcinoma in our data set (P = 0.62). Previous GWAS also report associations 
between this region and risk of  glioma (43), melanoma (28) and basal cell carcinoma (44) and a recent 
pleiotropy study indicated an association with esophageal SqCC (45). LD between variants reported in 
these studies and either rs62560775 or rs1011970 range from R2 = 0.21 to R2 = 0.60, indicating that 
multiple variants in this region contribute to cancer risk. Despite that associations for different cancers 
were exerted from multiple variants, our results represent an important pleiotropic finding, as all 
variants are located in the same gene, CDKN2B-AS1. 
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Modification of CDKN2B-AS1 activity could be the mechanism through which this locus influences cancer 
risk. CDKN2B-AS1, also known as ANRIL (antisense non-coding RNA in the INK4 locus) is known to recruit 
a polycomb repression complex (PRC2) that silences CDKN2B but not CDKN2A (46). Although there is no 
known function for rs62660775 or rs1011970, a variant with which rs62660775 is in strong LD, 
rs3217986 (at R2 = 0.75), was identified to be located in a miRNA binding site (47) and classified as likely 
to affect binding by Regulome. 
Our pleiotropy Q-Q plots (supplementary Fig. S4A-C) suggest pleiotropy between some sites: breast and 
ovarian cancer, breast and prostate cancer and prostate and lung cancer, with some evidence provided 
for pleiotropic associations involving prostate and lung and colorectal and ovarian cancer. There was 
little evidence for pleiotropic associations involving other site combinations using this approach.  
Although we have built in studies from non-European descendants, including Asians, African Americans 
and Hispanics, we did not observe an association with any of the loci in other ethnic groups.  It is likely 
that the smaller sample sizes for the non-European descendants restricted our power to detect 
associations. Variation in LD across ethnicities could also have reduced our power to detect associations. 
More research is needed to determine if associations in these regions can be generalized to different 
ethnic groups based on larger sample size. These efforts could make meaningful contributions to 
addressing disparities in health between populations.  
Power to detect associations is also relevant when considering our primary analyses involving subjects 
of European ancestry. Our initial investigation using the GAME-ON and GECCO data set identified 33 
regions and 190 variants that we further examined in replication data sets. We were able to replicate 
the associations for four of these regions. Since our replication datasets sample sizes were often smaller 
than that of our discovery (GAME-ON/GECCO) set (depending on cancer site), we may have insufficient 
power to replicate true associations particularly for less common variants, underlining the importance of 
sample size for investigations of pleiotropy.  
In summary, using data from the GAME-ON initiative and GECCO, we have found four regions that show 
associations with multiple cancers, including a novel association between genetic variation at 1q22 and 
breast cancer and lung squamous cell carcinoma. This is the largest study to date examining pleiotropy 
across multiple cancer sites. There are likely more loci that are associated with multiple cancers but 
these will require additional efforts with larger data series for detection.  Our results provide important 
insights into common carcinogenesis across multiple major cancers and highlight the value of pleiotropy 
analysis. 
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Figure Legends 
Figure 1. Result for rs1057941. Forest plot showing per allele ORs for risk allele A (of A/G). Standard fixed effects 
meta-analysis (also indicated by dashed line), and subset meta-analysis results (two-sided, one-sided and positive 
and negative subset associations) are shown. Abbreviations - CRC: colorectal, ERNEG: estrogen receptor negative, 
Aggrsv: aggressive, Adeno: Adenocarcinoma.  
 
Figure 2. Results for rs1057941 (A) Regional plot showing P values from overall meta-analysis at region 1q22 using 
GAME-ON/GECCO discovery set data. The top breast cancer hit (rs3814316) and top squamous cell carcinoma hit 
(rs4072037) are also highlighted. (B) Boxplots of gene expression levels in normal lung tissue for ADAM15 and 
THBS3 by study (Laval, UBC, Groningen). 
 
Figure 3. Results for rs13016963: (A) Forest plot showing per allele ORs for risk allele G (of A/G). Standard fixed 
effects meta-analysis (also indicated by dashed line), and subset meta-analysis results (two-sided, one-sided and 
positive and negative subset associations) are shown.  (B) Regional plot showing P values for GAME-ON prostate 
cancer GWAS at region 2q33.1 using GAME-ON/GECCO discovery set data. Peak is at ALS2CR12. (C) Boxplot of 
BZW1 gene expression levels in prostate tumor and normal tissue for rs1035142/rs13016963. rs1035142 is 
presented as a surrogate for rs13016963, with which it shows perfect LD in eQTL data. Abbreviations - CRC: 
colorectal, ERNEG: estrogen receptor negative, Aggrsv: aggressive, Adeno: Adenocarcinoma. 
Figure 4. Results for rs62560775: (A) Forest plot showing per allele ORs for risk allele G (of A/G). Standard fixed 
effects meta-analysis (also indicated by dashed line), and subset meta-analysis results (two-sided, one-sided and 
positive and negative subset associations) are shown. (B) Regional plot showing P values for GAME-ON lung 
adenocarcinoma GWAS at region 9p21.3, using GAME-ON/GECCO discovery set data. Peak is at CDKN2B-AS1. 
Results for rs1011970: (C) Forest plot showing per allele ORs for risk allele T (of T/G). Standard fixed effects meta-
analysis (also indicated by dashed line), and subset meta-analysis results (two-sided, one-sided and positive and 
negative subset associations) are shown. (D) Regional plot showing P values for GAME-ON prostate cancer GWAS 
at region 9p21.3, using GAME-ON/GECCO discovery set data. Peak is at CDKN2B-AS1. Abbreviations - CRC: 
colorectal, ERNEG: estrogen receptor negative, Aggrsv: aggressive, Adeno: Adenocarcinoma.  
 
 
 
 
 
 
 
 
 
 
Table 1. Contributing consortia and characteristics of data sets.  
 GAME-ON/GECCO Analysis 
 
Replication Stage  
(European ancestry) 
Generalizability  
(Other ancestry) 
Cancer Site 
(Consortium) 
No.  
studies Cases Controls
* Variants† Genotyping Platform 
Imputation 
threshold‡ 
 Study Cases Controls* Study Cases Controls* 
Lung (TRICL)10 6 12160 16838 8492272  
 
Illumina 
 
 
 
 
R2>0.3 
deCODE10,13 3865 196658 Nanjing18 2331 3077
 Harvard14,15 984 970
Adenocarcinoma  
 
3718 15871 8472145 
deCODE 1434 198663 Nanjing 1304 3077
 Harvard 597 970 Japan17 1575 3363
Squamous cell  
carcinoma  
 
3422 16015 8478230 
deCODE 784 171059 Nanjing 822 3077
 Harvard 216 970
      
 
 
   
    
Colorectal (CORECT)11 6 5100 4831 7229595 Affymetrix 
Axiom None 
deCODE 3546 236404 
Colorectal (GECCO)5  13 10314 12857 9193926 
Illumina, 
Affymetrix 
R2>0.3 
Prostate  (ELLIPSE) 
 
14160 12724 9084781  
Illumina, 
Affymetrix 
 
R2>0.3 
deCODE 4858 83103 LAPC/MEC20 1034 1046
6 iCOGS16 20219 20440 AAPC23 4853 4678
 JAPC/MEC20 980 1005
Prostate  
Aggressive 6 4450 12724 9003304 
Breast (DRIVE)7,9  
 
15748 18084 9331393 Illumina, 
Affymetrix R
2>0.3 
Shanghai19 2867 2285
11 
deCODE 
iCOGS7 
5318 
46785 
280808 
42892 
LABC/MEC, 
SF21 
1497 3213 
 AABC22 3015 2743
Breast ER6  8 4939 13128 9250406 
               
Ovary (FOCI)8  3 4369 9123 9911464 
Illumina  R2>0.3 
deCODE 716 111373
iCOGS8 16283 23491
Ovary - Serous  3 2556 9123 9911279 iCOGS 10316 23491
Ovary - 
Endometrial  3 715 9123 9910229  iCOGS 
2338 23491
Total* 45 61851 61820 9916564     55789 330490  18152 21410 
* The number of unique individuals after accounting for cancer subtypes and overlapping controls. Breast iCOGS included only 1q22 variants, so total for replicates without breast iCOGS is shown. †Subset 
meta-analyses were performed for a specific variant if at least 3 sites (i.e., three of lung, colorectal, prostate, breast or ovary) contributed data. ‡Imputation performed using the 1000 genome reference 
panel. Exclusion threshold shown. 
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